GBIO Quote, Financials, Valuation and Earnings

Codexis has a net margin of -202.71% compared to Generation Bio's net margin of -160.84%. Generation Bio's return on equity of -92.44% beat Codexis's return on equity of -79.15%.

Generation Bio has a consensus price target of $7.50, signalling upside risk potential of 530.25%. On the other hand Codexis has an analysts' consensus of $6.86 which suggests that it could grow by 35.73%. Given that Generation Bio has higher upside potential than Codexis, analysts believe Generation Bio is more attractive than Codexis.

Generation Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Codexis has a beta of 2.155, suggesting its more volatile than the S&P 500 by 115.515%.

Generation Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Codexis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Generation Bio pays -- of its earnings as a dividend. Codexis pays out -- of its earnings as a dividend.

Generation Bio quarterly revenues are $7.6M, which are smaller than Codexis quarterly revenues of $12.8M. Generation Bio's net income of -$15.3M is higher than Codexis's net income of -$20.6M. Notably, Generation Bio's price-to-earnings ratio is -- while Codexis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio is 4.26x versus 5.77x for Codexis. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI has a net margin of -202.71% compared to Generation Bio's net margin of --. Generation Bio's return on equity of -92.44% beat CEL-SCI's return on equity of --.

Generation Bio has a consensus price target of $7.50, signalling upside risk potential of 530.25%. On the other hand CEL-SCI has an analysts' consensus of -- which suggests that it could grow by 959.51%. Given that CEL-SCI has higher upside potential than Generation Bio, analysts believe CEL-SCI is more attractive than Generation Bio.

Generation Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.711%.

Generation Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Generation Bio pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Generation Bio quarterly revenues are $7.6M, which are larger than CEL-SCI quarterly revenues of --. Generation Bio's net income of -$15.3M is lower than CEL-SCI's net income of -$6.9M. Notably, Generation Bio's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio is 4.26x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

OraSure Technologies has a net margin of -202.71% compared to Generation Bio's net margin of -11.29%. Generation Bio's return on equity of -92.44% beat OraSure Technologies's return on equity of 2.69%.

Generation Bio has a consensus price target of $7.50, signalling upside risk potential of 530.25%. On the other hand OraSure Technologies has an analysts' consensus of $6.00 which suggests that it could grow by 64.84%. Given that Generation Bio has higher upside potential than OraSure Technologies, analysts believe Generation Bio is more attractive than OraSure Technologies.

Generation Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison OraSure Technologies has a beta of 0.034, suggesting its less volatile than the S&P 500 by 96.598%.

Generation Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OraSure Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Generation Bio pays -- of its earnings as a dividend. OraSure Technologies pays out -- of its earnings as a dividend.

Generation Bio quarterly revenues are $7.6M, which are smaller than OraSure Technologies quarterly revenues of $39.9M. Generation Bio's net income of -$15.3M is lower than OraSure Technologies's net income of -$4.5M. Notably, Generation Bio's price-to-earnings ratio is -- while OraSure Technologies's PE ratio is 24.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio is 4.26x versus 1.21x for OraSure Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Relmada Therapeutics has a net margin of -202.71% compared to Generation Bio's net margin of --. Generation Bio's return on equity of -92.44% beat Relmada Therapeutics's return on equity of --.

Generation Bio has a consensus price target of $7.50, signalling upside risk potential of 530.25%. On the other hand Relmada Therapeutics has an analysts' consensus of $10.88 which suggests that it could grow by 138.69%. Given that Generation Bio has higher upside potential than Relmada Therapeutics, analysts believe Generation Bio is more attractive than Relmada Therapeutics.

Generation Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Relmada Therapeutics has a beta of 0.353, suggesting its less volatile than the S&P 500 by 64.671%.

Generation Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Relmada Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Generation Bio pays -- of its earnings as a dividend. Relmada Therapeutics pays out -- of its earnings as a dividend.

Generation Bio quarterly revenues are $7.6M, which are larger than Relmada Therapeutics quarterly revenues of --. Generation Bio's net income of -$15.3M is higher than Relmada Therapeutics's net income of -$21.7M. Notably, Generation Bio's price-to-earnings ratio is -- while Relmada Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio is 4.26x versus -- for Relmada Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.